4.5 Review

Epigenetics: A primer for clinicians

Journal

BLOOD REVIEWS
Volume 30, Issue 4, Pages 285-295

Publisher

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2016.02.002

Keywords

5-Methylcytosine (5mC); Cytosine phospho-guanine (CpG); DNA methyltransferases (DNMTs); 5-Hydroxymethylcytosine (5HmC); DNMT inhibitor (DNMTi); Hypomethylating agent (HMA); Ten eleven translocation (TET)

Categories

Funding

  1. NIH [5T32CA009072-39]
  2. Roswell Park Alliance Foundation
  3. Roswell Park Cancer Institute
  4. RPCI's Cancer Center Support Grant from the NCI [P30CA016056]
  5. Sklarow Memorial Trust
  6. Astex Pharmaceuticals

Ask authors/readers for more resources

With recent advances in cellular biology, we now appreciate that modifications to DNA and histones can have a profound impact on transcription and function, even in the absence of changes to DNA sequence. These modifications, now commonly referred to as epigenetic alterations, have changed how we understand cell behavior, reprogramming and differentiation and have provided significant insight into the mechanisms underlying cardnogenesis. Epigenetic alterations, to this point, are largely identified by changes in DNA methylation and hydroxymethylation as well as methylation, acetylation, and phosphorylation of histone tails. These modifications enable significant flexibility in gene expression, rather than just turning genes ON or OFF. Herein we describe the epigenetic landscape in the regulation of gene expression with a particular focus on interrogating DNA methylation in myeloid malignancy. (C) 2016 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Meeting Abstract Oncology

Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.

Hamzah Abu-Sbeih, Faisal Ali, Abdul Rafeh Naqash, Dwight Hall Owen, Sandip H. Patel, Gregory Alan Otterson, Kari Lynn Kendra, Biagio Ricciuti, Rita Chiari, Andrea De Giglio, Joseph Sleiman, Pauline Funchain, Wills Beatriz, Jiajia Zhang, Jarushka Naidoo, Jessica Philpott, Jianjun Gao, Sumit Kumar Subudhi, Yinghong Wang

JOURNAL OF CLINICAL ONCOLOGY (2019)

Meeting Abstract Oncology

Tumor mutational burden (TMB) profile of K-RAS/TP-53co-mutation in metastatic non-small cell lung cancer (m-NSCLC).

Abdul Rafeh Naqash, Paul R. Walker, Mahvish Muzaffar, Rebecca Feldman, Maida Hafiz, Stephen V. Liu, Hirva Mamdani, Anokhi Patel, Hossein Borghaei, Nitika Sharma, Jorge J. Nieva, Yanis Boumber, Ari M. Vanderwalde, Patrick C. Ma, Ihab Eldessouki, David Craig Portnoy, Alexander I. Spira, Li V. Yang, Nagla Fawzy Abdel Karim

JOURNAL OF CLINICAL ONCOLOGY (2019)

Meeting Abstract Oncology

Spectrum of EGFR Exon 20 Insertion Mutations and Co-Occurring Genetic Alterations in Patients with Non-Small-Cell Lung Cancer

G. Bravo Montenegro, M. Nagasaka, P. Ma, A. R. Naqash, H. Mamdani, A. Spira, D. Subramaniam, R. Feldman, C. Kim

JOURNAL OF THORACIC ONCOLOGY (2019)

Article Oncology

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Abdul Rafeh Naqash, Biagio Ricciuti, Dwight H. Owen, Vaia Florou, Yukihiro Toi, Cynthia Cherry, Maida Hafiz, Andrea De Giglio, Mavish Muzaffar, Sandip H. Patel, Shunichi Sugawara, Jarred Burkart, Wungki Park, Rita Chiari, Jun Sugisaka, Gregory A. Otterson, Gilberto de Lima Lopes, Paul R. Walker

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

Letter Oncology

Recurrence of Immune-Mediated Colitis Upon Immune Checkpoint Inhibitor Resumption: Does Time Matter? Reply

Hamzah Abu-Sbeih, Faisal S. Ali, Dwight H. Owen, Biagio Ricciuti, Abdul Rafeh Naqash, Yinghong Wang

JOURNAL OF CLINICAL ONCOLOGY (2019)

Article Oncology

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

Hamzah Abu-Sbeih, David M. Faleck, Biagio Ricciuti, Robin B. Mendelsohn, Abdul R. Naqash, Justine V. Cohen, Maclean C. Sellers, Aanika Balaji, Guy Ben-Betzalel, Ibraheim Hajir, Jiajia Zhang, Mark M. Awad, Giulia C. Leonardi, Douglas B. Johnson, David J. Pinato, Dwight H. Owen, Sarah A. Weiss, Giuseppe Lamberti, Mark P. Lythgoe, Lisa Manuzzi, Christina Arnold, Wei Qiao, Jarushka Naidoo, Gal Markel, Nick Powell, Sai-Ching J. Yeung, Elad Sharon, Michael Dougan, Yinghong Wang

JOURNAL OF CLINICAL ONCOLOGY (2020)

Correction Oncology

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (vol 89, 451, 2020)

Abdul Rafeh Naqash, Biagio Ricciuti, Dwight H. Owen, Vaia Florou, Yukihiro Toi, Cynthia Cherry, Maida Hafiz, Andrea De Giglio, Mavish Muzaffar, Sandip H. Patel, Shunichi Sugawara, Jarred Burkart, Wungki Park, Rita Chiari, Jun Sugisaka, Gregory A. Otterson, Gilberto de Lima Lopes, Paul R. Walker

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

Article Oncology

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade

David J. Pinato, Takahiro Kaneko, Anwaar Saeed, Tiziana Pressiani, Ahmed Kaseb, Yinghong Wang, David Szafron, Tomi Jun, Sirish Dharmapuri, Abdul Rafeh Naqash, Mahvish Muzaffar, Musharraf Navaid, Chieh-Ju Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Neil Nimkar, Dominik Bettinger, Hannah Hildebrand, Yehia Abugabal, Celina Ang, Thomas U. Marron, Uqba Khan, Nicola Personeni, Lorenza Rimassa, Yi-Hsiang Huang

CANCERS (2020)

Article Oncology

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study

Petros Fessas, Ahmed Kaseb, Yinghong Wang, Anwaar Saeed, David Szafron, Tomi Jun, Sirish Dharmapuri, Abdul Rafeh Naqash, Mahvish Muzaffar, Musharraf Navaid, Uqba Khan, ChiehJu Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Neil Nimkar, Dominik Bettinger, Francesca Benevento, Hannah Hildebrand, Tiziana Pressiani, Yehia Abugabal, Nicola Personeni, Yi-Hsiang Huang, Lorenza Rimassa, Celina Ang, Thomas Marron, David J. Pinato

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Article Oncology

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy

David J. Pinato, Ahmed Kaseb, Yinghong Wang, Anwaar Saeed, David Szafron, Tomi Jun, Sirish Dharmapuri, Abdul Rafeh Naqash, Mahvish Muzaffar, Musharraf Navaid, Uqba Khan, ChiehJu Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Petros Fessas, Neil Nimkar, Dominik Bettinger, Hannah Hildebrand, Tiziana Pressiani, Yehia Abugabal, Nicola Personeni, Yi-Hsiang Huang, Jingky Lozano-Kuehne, Lorenza Rimassa, Celina Ang, Thomas U. Marron

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Article Biotechnology & Applied Microbiology

The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors

Arjun Mittra, Naoko Takebe, Vaia Florou, Alice P. Chen, Abdul Rafeh Naqash

Summary: Rare cancers, which account for approximately 20% of adult cancers in the US, have been underrepresented in research and clinical trials, leading to limited treatment options. The recent introduction of immune checkpoint inhibitors has started to show promise in the treatment of certain rare cancers, with efficacy depending more on tumor intrinsic factors and less on histology.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

Article Oncology

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer

Bairavi Shankar, Jiajia Zhang, Abdul Rafeh Naqash, Patrick M. Forde, Josephine L. Feliciano, Kristen A. Marrone, David S. Ettinger, Christine L. Hann, Julie R. Brahmer, Biagio Ricciuti, Dwight Owen, Yukihiro Toi, Paul Walker, Gregory A. Otterson, Sandip H. Patel, Shunichi Sugawara, Jarushka Naidoo

JAMA ONCOLOGY (2020)

Article Oncology

Cardiotoxicity risk factors with immune checkpoint inhibitors

Zachary L. Brumberger, Mary E. Branch, Max W. Klein, Austin Seals, Michael D. Shapiro, Sujethra Vasu

Summary: Checkpoint inhibitor immunotherapies have significantly improved the treatment of cancer by inhibiting T-cell response to malignancy. However, these agents can cause cardiotoxic events such as pericarditis and atrial fibrillation. This study identified female gender, African American race, and tobacco use as significant risk factors for these events.

CARDIO-ONCOLOGY (2022)

Meeting Abstract Oncology

Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).

Abdul Rafeh Naqash, Arjun Mittra, Geraldine Helen O'Sullivan Coyne, Li Chen, Biswajit Das, Shivaani Kummar, Khanh T. Do, Ting-Chia Chang, Ashley Bruns, Lamin Juwara, Brandon Miller, Robert J. Kinders, Ralph E. Parchment, Larry Rubinstein, Jiuping Jay Ji, Deborah Wilsker, Angie B. Dull, James H. Doroshow, Alice P. Chen, Naoko Takebe

JOURNAL OF CLINICAL ONCOLOGY (2020)

Meeting Abstract Oncology

Impact of baseline and concomitant corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy

David James Pinato, Ahmed Omar Kaseb, Yinghong Wang, Anwaar Saeed, David Szafron, Tomi Jun, Abdul Rafeh Naqash, ChiehJu Lee, Uqba Khan, Neil Satish Nimkar, Sonal D. Paul, Dominik Bettinger, Hannah Hildebrand, Tiziana Pressiani, Yehia I. Abugabal, Nicola Personeni, Yi-Hsiang Huang, Lorenza Rimassa, Celina Ang, Thomas Urban Marron

JOURNAL OF CLINICAL ONCOLOGY (2020)

No Data Available